Current progress and future perspectives of research on intravascular large B‐cell lymphoma

Cancer Science - Tập 112 Số 10 - Trang 3953-3961 - 2021
Kazuyuki Shimada1, Hitoshi Kiyoi1
1Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan

Tóm tắt

AbstractIntravascular large B‐cell lymphoma is a rare disease of the large B cells characterized by selective growth in the lumina of small vessels in systemic organs. Since first reported in 1959, the difficulty of obtaining sufficient tumor cells from biopsy specimens has hampered the elucidation of its underlying biology. Recent progress using xenograft models and plasma cell‐free DNA has uncovered genetic features that are similar to those of activated B‐cell type diffuse large B‐cell lymphoma, including MYD88 and CD79B mutations and frequent alterations in immune check point‐related genes such as PD‐L1 and PD‐L2. Given the improvement in clinical outcomes and a higher risk of secondary central nervous system (CNS) involvement in the rituximab era, a phase 2 trial of R‐CHOP combined with high‐dose methotrexate and intrathecal chemotherapy as a CNS‐oriented therapy has been conducted. This trial, the PRIMEUR‐IVL study, has displayed good progression‐free survival and a low cumulative incidence of secondary CNS involvement. Long‐term follow‐up within this trial is still ongoing. Further understanding of the pathophysiology of the disease and improvements in clinical outcomes are still needed.

Từ khóa


Tài liệu tham khảo

Nakamura S, 2017, WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 317

Nakamura S, 2008, WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 252

10.1080/10428194.2017.1287363

10.1200/JCO.2007.15.4278

10.1016/S0046-8177(00)80223-3

10.1038/leu.2016.67

10.1038/35000501

Gascoyne RD, 2017, WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 291

10.1182/blood-2006-01-021253

10.1182/blood-2003-05-1545

10.1182/blood-2005-02-0542

10.1038/nature10351

10.1038/ng.892

10.1016/j.cell.2017.09.027

10.3324/haematol.2017.178830

10.1182/blood-2017-12-822817

10.1182/blood.2020007245

10.1056/NEJMoa1801445

10.1016/j.ccell.2020.03.015

10.1111/j.1365-2141.2000.02426.x

10.1111/j.1365-2141.2004.05177.x

10.1111/pin.12742

10.1002/cam4.3104

10.1111/his.13870

10.1038/nature18294

10.1111/pin.12757

10.1111/bjh.15923

10.1016/S1470-2045(20)30059-0

10.1002/ajh.20099

10.1179/acb.2007.031

10.1002/hon.876

10.1007/s12185-008-0102-7

Shi X, 2019, The Role of 18F‐FDG PET/CT in the Assessment of Patients with Intravascular Large B‐Cell Lymphoma, J Nucl Med, 60, 1249

10.1136/jnnp.2003.033662

10.1007/s00277-018-3481-8

10.1016/S0025-6196(11)61097-5

10.1007/s00277-010-1101-3

10.1111/bjd.17603

10.1182/blood-2018-11-887570

10.1111/1346-8138.12756

Shimada K, 2010, Intravascular large B‐cell lymphoma; recent advances and future perspectives, Rinsho Ketsueki, 51, 447

10.1002/hon.2489

10.1097/WCO.0000000000000869

10.1007/s00277-021-04572-2

10.1200/JCO.1994.12.12.2573

10.1093/annonc/mdh274

10.3960/jslrt.48.25

10.1111/j.1365-2141.2008.07338.x

10.1200/JCO.2008.19.1841

10.1111/j.1349-7006.2010.01555.x

10.1200/JCO.2015.65.6520

10.1056/NEJMoa011795

10.1016/S1470-2045(06)70664-7

10.1182/blood-2010-03-276246

10.1111/bjh.12585

10.1038/s41409-019-0491-7

10.1097/MD.0000000000005985

10.1038/s41591-018-0016-8

Thông tin
Thông tin xuất bản

Cancer Science

Tập 112 Số 10

3953-3961

Thông tin tác giả